- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 28-05-2026: Press Release
28-05-2026 | 11:10 am
28-05-2026 | 11:10 am
Lupin shared positive Phase 1a trial data for LNP8701, a novel SOS1 inhibitor for solid tumors, at ASCO. The drug demonstrated good safety and preliminary anti-tumor activity, with some patients achieving stable disease. Further studies are planned.
No comments yet. Be the first to comment!